Featured Research

from universities, journals, and other organizations

Ovarian cancer subtypes may predict response to bevacizumab

Date:
June 1, 2014
Source:
Mayo Clinic
Summary:
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a study has found. The U.S. spends about $3 billion a year on bevacizumab for cancer treatment. "Unfortunately, two-thirds of those patients don't respond to the drug, which means we are just giving them toxicity with no benefit. This expression data will help us choose which patients should receive this drug," a researcher notes.

Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented at the 2014 American Society of Clinical Oncology Annual Meeting.

The addition of bevacizumab to standard therapy extended progression-free survival more for ovarian cancer patients with molecular subtypes labeled as "proliferative" or "mesenchymal" compared to those with subtypes labeled as "immunoreactive" or "differentiated," says Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist and senior author of the study. "Though our study is very preliminary, it does suggest that we are getting close to the point where we could use sequencing data to choose more effective and less toxic therapies for patients."

Dr. Dowdy says the U.S. spends about $3 billion a year on bevacizumab for cancer treatment. "Unfortunately, two-thirds of those patients don't respond to the drug, which means we are just giving them toxicity with no benefit. This expression data will help us choose which patients should receive this drug."

Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels that help cancers grow and spread. An international phase 3 clinical trial known as ICON7 has recently shown that adding this drug to the first-line chemotherapy drugs carboplatin and paclitaxel can improve progression-free survival of ovarian cancer patients.

Dr. Dowdy and his colleagues wanted to determine if the response to this new treatment could be predicted by looking at the molecular makeup of ovarian tumors. First, the researchers used gene expression arrays to analyze biopsies preserved in paraffin-embedded tissue blocks from ICON7 patients.

Then, they used the molecular classification already established by the National Cancer Institute's Cancer Genome Atlas (TCGA) project to separate the patients into four subtypes of the disease, based on precise patterns of genes that had been turned "on" or "off" in their tumors. Of the 359 patients studied, 20 percent had the differentiated subtype, 34 percent had the immunoreactive subtype, 19 percent had the mesenchymal subtype, and 27 percent had the proliferative subtype.

Finally, Dr. Dowdy and his colleagues looked for an association between these molecular subtypes and responses to treatment. They found that patients with the proliferative and mesenchymal subtypes fared the best, with 10.1-and 8.1-month improvements in progression-free survival after treatment with bevacizumab, respectively. In comparison, patients with the immunoreactive and differentiated subtypes only experienced an improvement of 3.8 and 3.7 months, respectively. Similar differences were seen between subtypes when the investigators looked at another measure of treatment response, overall survival.

"It makes sense that patients with proliferative and mesenchymal subtypes would respond the most favorably to bevacizumab, because the same genes and molecular pathways that are implicated in those subtypes are also the ones affected by the drug," says Dr. Dowdy.

Once the rest of the data from the ICON7 trial are published, Dr. Dowdy and his colleagues plan to reanalyze their results to see if even stronger associations can be found between subtypes and outcomes.

They also hope to validate their results in another set of patients, a necessary step before molecular sequencing can identify the patients most likely to respond to this particular drug.

"Right now bevacizumab is not universally used in the first-line treatment of ovarian cancer in the United States because it gives marginal improvement in survival, is extremely expensive at about $100,000 per year, and may have toxic side effects," says Dr. Dowdy. "But if we could identify those patients who will see a 10-month improvement in progression-free survival, it would be worth treating them with the drug. On the other hand, avoiding the use of bevacizumab in patients unlikely to respond will allow us to reduce unnecessary toxicity and prescribe other, potentially more effective drugs for that particular patient."


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Ovarian cancer subtypes may predict response to bevacizumab." ScienceDaily. ScienceDaily, 1 June 2014. <www.sciencedaily.com/releases/2014/06/140601201956.htm>.
Mayo Clinic. (2014, June 1). Ovarian cancer subtypes may predict response to bevacizumab. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/06/140601201956.htm
Mayo Clinic. "Ovarian cancer subtypes may predict response to bevacizumab." ScienceDaily. www.sciencedaily.com/releases/2014/06/140601201956.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins